PD-1/PD-L1轴与慢性阻塞性肺疾病的免疫病理研究进展

The immunopathology and the role of PD-1/PD-L1 axis in chronic obstructive pulmonary disease

COPD的特征在于持续的气道炎症和不可逆的气流受限,全球发病率、病死率均很高。越来越多的研究表明COPD患者存在免疫缺陷,其中程序性死亡蛋白1/程序性死亡蛋白配体1(PD-1/PD-L1)轴与炎症反应受损、急性加重风险提高密切相关。阻断PD-1/PD-L1轴可调节免疫反应并改善免疫状态,结合常规药物可提高COPD总体治疗效果。本文旨在总结COPD患者的免疫缺陷及PD-1/PD-L1轴参与其中的作用,为COPD新的治疗方法提供参考。

Chronic obstructive pulmonary disease(COPD)is characterized by persistent airway inflammation and irreversible airflow limitation,with high global morbidity and mortality.More and more studies show that COPD patients have immunodeficiency,and the programmed death protein 1/programmed death protein ligand 1(PD-1/PD-L1)axis is closely associated with impaired inflammatory response and increased risk of acute exacerbations.Blocking the PD-1/PD-L1 axis can regulate the immune response and improve the immune status,combined with conventional drugs can improve the overall therapeutic effect of COPD.This article aims to summarize the immunodeficiency of patients with COPD and the role of PD-1/PD-L1 axis,and provide a reference for new treatments for COPD.